Yukako Ito

Dr. Yukako Ito


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2006 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
YIYukako Ito
Yukako Ito
EHEiji Hagiwara
Eiji Hagiwara
ASAtsushi Saeki
Atsushi Saeki
NSNobuyuki Sugioka
Nobuyuki Sugioka
KTKanji Takada
Kanji Takada

1 January 2006 in Journal of Drug Targeting
Verified
Journal Article
Closed access
YIYukako Ito
Yukako Ito
JYJun-Ichiro Yoshimitsu
Jun-Ichiro Yoshimitsu
KSKeiji Shiroyama
Keiji Shiroyama
NSNobuyuki Sugioka
Nobuyuki Sugioka
KTKanji Takada
Kanji Takada
Erythropoietin (EPO) loaded microneedles were prepared using thread-forming polymer as a base for the percutaneous administration of EPO. The used polymers were dextrin, chondroitin sulfate and albumin. Under room temperature, EPO solution was added to high concentration of polymer solution and microneedles were prepared by forming thread with polypropylene tips. The mean weight of microneedle was 0.59 +/- 0.01 mg and length and basal diameter were 3.24 +/- 0.16 and 0.55 +/- 0.03 mm, respectively. Four microneedles were percutaneously (pc) administered to mice at the EPO dose levels of 100 IU/kg. After administration, blood samples were collected for 24 h and serum EPO levels were measured. Dextrin EPO microneedles were administered both pc and subcutaneously (sc) to mice. Serum EPO levels vs. time profiles showed Cmax of 138.6 +/- 16.1 and 146.5 +/- 8.0 mIU/ml, respectively. Tmax were 7.5 h. The values of bioavailability (BA) of EPO were 82.1 and 99.4%, respectively. By decreasing the dose from 100 to 50 and 25 IU/kg, dose-dependent serum EPO levels vs. time profiles were not clearly obtained. When chondroitin sulfate and albumin were used as the microneedle base, the serum EPO levels vs. time profiles showed almost the same pattern. Cmax of chondroitin sulfate and albumin microneedles were 96.3 +/- 8.8 and 132.2 +/- 18.9 mIU/ml, respectively. AUCs were 835.1 and 1098.7 mIU h/ml. Tmax were 8 and 6.8 h. These results suggest the usefulness of microneedles for the percutaneous administration of EPO.

1 June 2005 in Journal of Controlled Release
Verified
Journal Article
Closed access
YIYukako Ito
Yukako Ito
TKTomohiro Kusawake
Tomohiro Kusawake
MIMakoto Ishida
Makoto Ishida
RTRiichi Tawa
Riichi Tawa
NSNobuhito Shibata
Nobuhito Shibata
KTKanji Takada
Kanji Takada

1 October 2012 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
YIYukako Ito
Yukako Ito
MHMuneyuki Hirono
Muneyuki Hirono
KFKeizo Fukushima
Keizo Fukushima
NSNobuyuki Sugioka
Nobuyuki Sugioka
KTKanji Takada
Kanji Takada

1 April 2011 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
YIYukako Ito
Yukako Ito
HMHiroshi Murano
Hiroshi Murano
NHNoriyuki Hamasaki
Noriyuki Hamasaki
KFKeizo Fukushima
Keizo Fukushima
KTKanji Takada
Kanji Takada

1 February 2008 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
YIYukako Ito
Yukako Ito
AMAiko Murakami
Aiko Murakami
TMTomohiro Maeda
Tomohiro Maeda
NSNobuyuki Sugioka
Nobuyuki Sugioka
KTKanji Takada
Kanji Takada